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ABSTRACT
Background: Thrombosis is a common complication in 
Type 2 Diabetes Mellitus (T2DM). Prolonged APTT 
values have clinical relevance as an indicator of factor 
deficiency or the presence of coagulation inhibitors. 
However, there is mounting evidence that shortened 
APTT values in some cases may reflect a 
hypercoagulable state, which is potentially associated 
with increased thrombotic risk and adverse 
cardiovascular events. We set out a cross-sectional study 
to measure the haemostatic profiles of T2DM patients and 
to determine the suitability of PT-APTT as markers for 
hypercoagulability in T2DM patients using VWF as a 
gold standard. 
Methods:  PT, APTT, VWF and Fibrinogen 
concentrations were measured in 213 T2DM patients and 
172 non-diabetic healthy participants. VWF was used as a 
proxy marker for hypercoagulability in T2DM patients. 
Participants with VWF of >2.0 IU/ml , PT and APTT less 
than 11 and 30 seconds respectively, were regarded as 
being in hypercoagulable state. 
Results: The results revealed that mean fibrinogen 
concentration for T2DM patients (4.3 ±2.5g/l) was 
significantly higher than control participants (2.3±1.6 
g/l); P-value = 0.003.The mean Vonwillebrands factor 
concentration for T2DM patients (7.4 ±4.1 IU/ml) was 
significantly higher than control participants (2.6±2.2 
IU/ml).  P-value = 0.0004. The mean Prothrombin Time 
for T2DM patients (12.4±3.3 seconds) was lower than 
control participants (12.5 ±2.9 seconds) but the difference 
was not significant P-value = 0.168. The mean APTT for 
T2DM patients (24.7 ±3.8seconds) was significantly 
lower than control participants (32.2±4.2seconds).  P 
value = 0.000. The study further revealed that APTT tests 
were more sensitive 93.7% (95% CI [88.0-96.7)] than PT 
test which had a sensitivity of 55.6% (95% CI [46.8-
63.9)]. Both APTT and PT tests had better specificity; 
however APTT was higher 95.4% (95% CI [88.8-98.2]) 
than PT test 90.8% (95% CI [82.9-94.3]). APTT test had a 
higher PPV 96.7% (95% CI [91.9-98.7)] than PT test 
89.7% (95% CI 81.0 94.7]). PT test gave a much lower 
NPV 58.5% (95% CI [50.0-66.5]) as compared to APTT 
tests which had a higher NPV 91.2% (95% CI [83.6-
94.5]). 
Conclusion: Haemostatic profile results show that T2DM 
patients are more hypercoagulable than non-diabetic 
healthy individuals. APTT had a better diagnostic 
specificity and sensitivity than PT. It is cheaper, easier to 
do and has high PPV and NPV compared to PT. APTT 
could therefore be used as a marker for hypercoagulability 
in T2DM patients.
INTRODUCTION
Thrombosis is the leading cause of morbidity and 
mortality in patients with diabetes mellitus. Eighty percent 
Key words: Hypercoagulability, VWF, Type 2 diabetes 
mellitus, APTT, NPV, PPV
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of patients with diabetes mellitus die due to thrombosis, 
and 75% of these deaths are due to cardiovascular 
complications (1).  At Ndola Central Hospital (NCH) 
more than 50% of patients admitted for cardiovascular 
complications, have T2DM. (2).
Several mechanisms contribute to diabetic prothrombotic 
state. These include endothelial dysfunction, coagulative 
activation and platelet hyper-reactivity. In particular, 
diabetic platelets are characterized by deregulation of 
several signalling pathways leading to enhanced 
adhesion, activation and aggregation (3). These 
alterations result from the interaction between 
hyperglycemia, insulin resistance, inflammation and 
oxidative stress. The prothrombotic or hypercoagulable 
state is not easily detected by routine laboratory tests 
unlike the hypocoagulable state. So far, no coagulation 
screening test is available to detect a hypercoagulable 
state, whether it is due to congenital or acquired 
thrombotic disorders, with the exception of lupus 
anticoagulant (LA). In hypocoagulable state, APTT is a 
useful screening test in the investigation of bleeding 
disorders. Prolonged APTT and corrected result after 
mixing test is most likely to be associated with 
hypocoagulable disorder due to coagulation factor(s) 
deficiency (4). 
Although modern coagulation diagnostic tests are 
becoming more sophisticated, standard coagulation 
screening tests, such as activated partial Thromboplastin 
time (APTT) and Prothrombin time (PT) are still 
important basic examinations in clinical laboratories. 
APTT is commonly used to test the intrinsic coagulation 
pathway; whereas prolonged APTT is a clinical indicator 
of either a factor deficiency or the presence of coagulation 
inhibitors (5). The APTT assay is traditionally used for 
identifying abnormalities in the contact (factor XII, 
prekallikrein, and high-molecular-weight kininogen), 
intrinsic (factors XI, VIII, IX) and common (factors X, V 
and II and fibrinogen) pathways of coagulation (6). 
Prolonged APTT values have clinical relevance as an 
indicator of factor deficiency or the presence of 
coagulation inhibitors. However, there is mounting 
evidence that shortened APTT values in some cases may 
reflect a hypercoagulable state, which is potentially 
associated with increased thrombotic risk and adverse 
cardiovascular events (5,7). Shortened APTTs may result 
from an accumulation of circulating activated 
coagulation factors in plasma caused by enhanced 
coagulation activation in vivo (5,7). 
From the literature searched so far no studies were found 
that have explicitly evaluated PT and APTT as markers of 
hypercoagulation in terms of Sensitivity, Specificity, 
Positive and Negativity predictive values. This is the first 
study to evaluate PT and APTT as markers of 
hypercoagulation in T2DM patients. Soltan et al., (2011) 
and Lip et al., (2010), have shown Von Willebrands and 
fibrinogen to be predisposing factors for thrombotic 
development in T2DM patients and have been widely 
used as markers for hypercoagulability in T2DM patients 
(8,9). However most assays designed to estimate plasma 
von willebrands factor concentration are very expensive 
and tedious to perform and hence cannot be done 
routinely in most laboratories in Zambia. The total cost of 
analyzing a sample for vonwillebrands factor is about 30 
US dollars, while the cost of PT, APTT and Fibrinogen 
test is less than 3 US dollars per sample. Though 
fibrinogen is comparable to PT and APTT in terms of cost, 
it is also an acute phase protein hence can increase in other 
inflammatory conditions, thus making it a non-specific 
marker for hypercoagulation (10). There is no data 
available regarding haemostatic profile and prevalence of 
hypercoagulability among Type 2 Diabetes Mellitus 
patients in Zambia. Many of the previous studies on 
haemostatic changes in diabetic Patients have been 
conducted in Europe and Asia. Currently in Zambia, 
haemostatic profile tests are not part of tests done in the 
management of T2DM patients.  Furthermore the 
prognosis is not good when diabetic patients suffer from 
cardiovascular or cerebrovascular thrombotic diseases. 
Early detection of the prothrombotic state is therefore 
critical for the administration of preventive therapy in 
T2DM patients. Therefore inclusion of the haemostatic 
tests in the management of T2DM patients will result in 
commencement of early treatment in those patients 
suspected to be in hypercoagulable state and hence 
reduction of deaths occurring as a result of thrombosis. 
It was therefore cardinal that a study was done to 
determine hypercoagulability status of T2DM patients 
and evaluate PT and APTT as markers for 
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hypercoagulability using VWF as a gold standard. This is 
very vital; especially that PT and APTT can easily be done 
in most laboratories as these tests are cheaper to perform 
and reagents are readily available. 
The aim of this study was to measure the haemostatic 
profile of T2DM patients and evaluate the suitability of 
PT-APTT as markers for hypercoagulability state in 
T2DM patients using vWF as a gold standard.
MATERIALS AND METHODS
This study was conducted at Ndola Central Hospital, a 
third level referral hospital for Copperbelt and Northern 
part of Zambia. It is located in Ndola, the provincial 
headquarters of the Copperbelt Province. The hospital has 
a bed capacity of 851. 
The study was a cross-sectional descriptive study 
involving T2DM patients attending Ndola Central 
Hospital Out-patient Department (OPD) Diabetic clinic 
and healthy adult male and female participants visiting 
OPD for medical examinations between November 2012 
to May 2013. The total number of participants recruited in 
this study was 385. This included 213 T2DM patients and 
172 healthy adult individuals as control participants.
Convenience sampling was used to recruit 213 T2DM 
patients and 172 non-diabetic healthy controls attending 
medical examinations at Ndola Central Hospital.
Inclusion and exclusion criteria
Inclusion criteria
The study included male and female T2DM patients and 
Non-diabetic healthy individuals above the age of 18 
years. 
Exclusion criteria
Part ic ipants  who had a  his tory of  venous 
thromboembolism or known inherited coagulation 
disorders, Cancer and hyperthyroidism were excluded 
from the study. Others excluded include, those who were 
Pregnant, had recent surgery, those taking standard 
anticoagulant treatment, less than 18 years and those not 
willing to consent. 
Data collection
Good Laboratory Practice (GLP) principles according to 
the Ministry of health laboratory quality manual was 
observed to ensure uniformity, consistency, reliability and 
reproducibility of all the laboratory test results produced 
in this study. Venous blood collection was done by using 
the evacuated blood collection system. 3 ml of venous 
blood was collected for each test. Three (3) ml of venous 
blood for PT and APTT was collected from each of the 
study participants in sodium citrate containers and 
centrifuged at 1500g for 15 minutes. Plasma was then 
separated and transferred into siliconized glass tubes and 
stored at 4C in a fridge until analysis. The reagents used 
for PT and APTT were sourced from SPINREACT 
Diagnostics Company of Spain. PT and APTT results 
were reported in seconds. Any participants' PT and APTT 
results which were below 11 seconds and 30 seconds 
respectively were considered as being hypercoagulable 
state.
Blood for fibrinogen determination was collected from 
the study participants in sodium citrate containers and 
centrifuged at 1500g for 15 minutes. Plasma was then 
separated and transferred into plastic or siliconized glass 
tubes and stored at -20C until analysis. The reagents for 
this test were sourced from SPINREACT Diagnostics 
Company of Spain. 
The kit used utilizes the thrombin clotting time assay 
based on the method originally described by Clauss (11). 
The reference range for fibrinogen concentration was 
taken as 1.6 to 3.2 g/l. Any participants' fibrinogen result 
above 3.2 g/l concentration was regarded as 
hypercoagulable state.
The same participants' plasma samples for PT and APTT 
analysis as prepared above was also used for vWF 
analysis. VWF was determined by the Human ELISA kit 
manufactured by Abnova of USA. Plasma VWF 
concentration results were reported in International 
units/ml (IU/ml).The reference range for plasma 
concentration of vWF is 0.6 to 2.0 IU/ml. Any result 
above 2.0 IU/ml was regarded as being in 
hypercoagulable state.
Sensitivity, Specificity, Positive and negative Predictive 
va lues  fo r  PT and  APTT as  markers  fo r  
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hypercoagulability were determined. VWF concentration 
was used as a proxy standard method for 
hypercoagulability and this was compared to PT and 
APTT results for each patient. The cross tabulation tables 
obtained from SPSS between VWF results in comparison 
to PT/APTT were transferred to CEBM (Center for 
evidence Based Medicine) Statistics Calculator for 
calculation of sensitivity, specificity, positive and 
negative predictive values.
Ethical considerations
This study was performed under a protocol that was 
reviewed and approved by the University of Zambia-
Biomedical Research Ethics Committee (UNZA-BREC). 
Written permission was obtained from the Permanent 
Secretary in the Ministry of Health as well as from the 
Senior Medical Superintendent of Ndola Central 
Hospital. All the prospective participants in this study 
were informed about the study, privileges and right to 
participation. The purpose of the study was thoroughly 
explained to the participants and those that declined to 
participate in the study were not forced, but were assured 
of their protected privileges and rights to treatment. 
Privacy and confidentiality was maintained. The names 
of the respondents did not appear anywhere on the forms 
instead codes were used on the forms. The forms were 
kept in lockable cabinets and no one apart from the 
researcher had access to the cabinets. Data on the 
computer was pass-word protected such that access was 
limited to only the researcher.  Consenting patients and 
control participants were made to sign the consent form 
before being enrolled into the study.
Data analysis
The Statistical Package for Social Science (SPSS version 
16) and CEBM Statistics Calculator was used to analyse 
the results statistically. Analysis of distribution was made 
using the Kolmogoroff-Smirnoff test. All the parameters 
were normally distributed and hence reported as the mean 
+/- standard deviation. The significance of the differences 
between patients and controls for normally distributed 
parameters were determined using the independent 
samples T-test. Sensitivity, Specificity and Positive 
predictive value for PT-APTT as markers for 
hypercoagulability were calculated from a 2x2 table 
computed in CEBM Statistics Calculator.  P-values of 
less than 5% were taken as significant.
RESULTS 
An independent-sample t-test was conducted to compare 
the haemostatic profiles in T2DM and control 
participants. Table I and figure I, reveals that mean 
fibrinogen concentration for T2DM patients (4.3 ±2.5g/l) 
was significantly higher than control participants 
(2.3±1.6 g/l); P-value = 0.003.
The mean Vonwillebrands factor concentration for T2DM 
patients (7.4 ±4.1 IU/ml) was significantly higher than 
control participants (2.6±2.2 IU/ml); P-value = 0.0004.
The mean Prothrombin Time for T2DM patients 
(12.4±3.3 seconds) was lower than control participants 
(12.5 ±2.9 seconds) but the difference was not significant; 
P-value = 0.168.
Table I: Haemostatic profiles in type 2 diabetes mellitus 
patients and control 
Subjects.    Independent t-test parameters.
Figure I: Comparison of mean haemostatic profiles 































































APTT (Seconds) Male 93 32.0 3.0
0.001
Female 120 28.3 3.5
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The mean Activated Partial Thromboplastin Time for 
T2DM patients (24.7 ±3.8seconds) was significantly 
lower than control participants (32.2±4.2seconds; P value 
= 0.000.
Table II and III illustrates the crosstabulations of VWF 
results in comparison to the PT and APTT test results. 
Table 4 reveals that 126(59.1%) of the participants were 
hypercoagulable (had VWF results of greater than 2.0 
IU/ml). Out of these results,70(32.9%) participants 
results were true positives, implying that both the VWF 
test results and the prothrombin time were abnormal. 
8(3.7%) of the results were false positive test results with 
the prothrombin test but the patients were not 
hypercoagulable because the VWF results were below 
2.0 IU/ml. 56 (26.3%) of the participants results were 
false negatives, implying that the prothrombin test results 
were negative but the participants were in actual fact 
hypercoagulable. 79(37.1%)  negative prothrombin test 
results were true negatives because the VWF results were 
also positive, implying that the patients were 
hypercoagulable. Table IV reveals that 118(54.3%), 
4(1.9%), 8(3.7%) and 83(39.0%) APTT test results were 
True Positives, False Positives, False negatives and True 
Negatives respectively. Table IV reveals that APTT tests 
were more sensitive 93.7% (95% CI [88.0-96.7)] than PT 
test which had a sensitivity of 55.6% (95% CI [46.8-
63.9)]. Both APTT and PT tests had better specificity; 
however APTT was higher 95.4% (95% CI [88.8-98.2]) 
than PT test 90.8% (95% CI [82.9-94.3]). APTT test had a 
higher PPV 96.7% (95% CI [91.9-98.7)] than PT test 
89.7% (95% CI 81.0 94.7]). PT test gave a much lower 
NPV 58.5% (95% CI [50.0-66.5]) as compared to APTT 
tests which had a higher NPV 91.2% (95% CI [83.6-
94.5]). This entails that APTT is a better predictor of 
hypercoagulable state than PT in T2DM patients. 
Furthermore, APTT is a better discriminator for non-
hypercoagulable states in T2DM patients. 
DISCUSSION
It was observed in this study that the Prothrombin time 
(PT) of diabetic subjects (12.4± 3.3 seconds) was 
insignificantly shorter than that of non diabetic controls 
(12.5± 2.9 seconds) P= 0.168. Partial thromboplastin 
time (APTT) in the diabetic subjects was significantly 
shorter than that of controls (P=0.000). The results for 
PT test  Vonwillebrands factor  
TotalHypercoagulable  
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Table II: Comparison of VWF results and PT test results 
in type 2 diabetes mellitus patients
Table III: Comparison of VWF results and APTT test 
results in type 2 diabetes mellitus patients
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TP: True Positive TN: True Negative FP: False Positive 
FN: False Negative









PT  55.6  90.8 89.7 58.5
APTT  93.7  95.4 96.7 91.2
Prothrombin Time accords that of Zhao et al.,(2011) who 
found insignificant shortened PT in T2DM patients as 
compared to control subjects (12). The results are also 
consistent with Lippi et al., (2009), who found shortened 
PT and APTT in T2DM patients than in non-diabetes 
control subjects, but only the APTT results were 
significantly shorter (7). Boekel et al., (2002) reported that 
PT and APTT tests are standard screening tests for 
function of the coagulation system and their utility in 
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monitoring therapeutic anticoagulation is widely 
accepted (13). Prolonged APTT values have clinical 
relevance as an indicator of factor deficiency or the 
presence of coagulation inhibitors. Shortened APTTs are 
generally considered to be laboratory artifacts arising 
from problematic venepunctures. However, there is 
mounting evidence that shortened APTT values in some 
cases may reflect a hypercoagulable state, which is 
potentially associated with increased thrombotic risk and 
adverse cardiovascular events (5,7). Shortened APTTs 
may result from an accumulation of circulating activated 
coagulation factors in plasma caused by enhanced 
coagulation activation in vivo (5,7). 
Acang et al., (2005) observed that there were 
significantly shortened PT and APTT values, in diabetic 
patients, especially in patients with long-term diabetes 
with chronic complications, which are consistent with 
the results of this study ((14). The insignificant PT results 
support the hypothesis that there is less involvement of 
the extrinsic pathway in hypercoagulability state in 
diabetic conditions due to the fact that injury occurring to 
the vascular system in diabetic patients does not involve 
tissue factor from outside the vascular system (8). Korte 
et al. (2008) reported that patients presenting with 
shortened APTT values had increased thrombin 
generation, were in a complex hypercoagulant state and 
were at increased risk for thromboembolism(15). Tripodi 
et al. (2004) found that hypercoagulability detected by 
shortened APTT values was independently associated 
with venous thromboembolism (VTE) and hypothesized 
that shortened APTT could be considered as a risk marker 
for VTE (6). 
The mean fibrinogen concentration of persons with 
diabetes in this study was significantly higher than the 
concentration in the controls (P < 0.05). This higher 
fibrinogen concentration found in the diabetic group 
agrees with Mark's report (2001) of elevated fibrinogen 
concentration as one of the risk factors for atherosclerosis 
among diabetics (16). The findings also accords that of 
Zhao et al., (2011) who reported increased Fibrinogen 
concentrations among Chinese T2DM patients (12). 
Fibrinogen may induce thrombus formation by affecting 
platelets and erythrocytes to aggregation and by 
promoting increased blood viscosity (17). Kannel et al., 
(2005) reported that fibrinogen is often elevated in T2DM 
patients and this elevation is associated with poor 
glycaemic control (18). The increase in fibrinogen levels 
in T2DM patients may be due to chronic fibrinogen 
synthesis. Increased fibrinogen levels in diabetes may be 
related to the associated low-grade inflammation. 
Interleukin (IL)-6 levels are elevated in diabetes and this 
cytokine is able to stimulate hepatocytes to produce 
fibrinogen, representing an important link between 
inflammation and hypercoagulation. In an hyperglycemic 
environment, fibrinogen can become hyperglycosylated, 
when this abnormal fibrinogen clots, the resulting fibrin 
structure is composed of small diameter fibers that are 
markedly resistant to degradation by plasmin hence 
increase in hypercoagulability (12).
In the current study, the mean von willebrands factor 
concentration was higher in T2DM patients (7.4 ± 4.1 
IU/ml) than the control participants (2.6± 2.2 IU/ml). This 
accords the results obtained by Mohamed et al., (2005), 
who found increased VWF levels in T2DM patients than 
control participants (19). The findings also correlates 
with Alzahrani et al., (2010), who found elevated VwF 
concentrations in T2DM patients as compared to non-
diabetic control participants (20). Soltami et al., (2011) 
also obtained elevated vWF in T2DM patients than the 
control subjects (8). VWF is also known as a marker for 
endothelium damage and in turn is increased in T2DM 
patients (21,22,23). VWF is produced by endothelial cells 
and megakaryocytes throughout the body (24). Levels of 
circulating vWF are increased following endothelial cell 
damage. Several mechanisms contribute to the 
endothelial dysfunctional phenotype in T2DM patients 
including altered glucose metabolism, impaired insulin 
signalling, low-grade inflammatory state, and increased 
reactive oxidant species (ROS) generation. Enhanced 
oxidative stress in the hyperglycaemic milieu accelerates 
the glycoxidation of proteins and lipids to generate 
advanced glycation end products (AGEs) (25). AGEs 
accumulate in the vessel wall, where they may directly 
disturb cell structure and function and hence exposure of 
the vWF which is always found in the sub endothelium 
layer. The mean Fibrinogen and Vonwillebrands factor 
were significantly increased in Female T2DM patients 
than in male patients. P-values 0.017 and 0.001 
respectively. 
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The study revealed that PT test had more false negative 
results which culminated in a much lower sensitivity 
55.6% (95% CI [46.8-63.9)] than the APTT test which had 
low False negative results and hence a better sensitivity of 
93.7% (95% CI [88.0-96.7)] This implies that the PT test 
is only capable of detecting 55.6% of hypercoagulable 
cases among  T2DM patients and therefore 44.4% of the 
cases will be missed as these will be regarded as negative 
while in the actual fact they are positive cases. On the 
contrary APTT test had a better sensitivity of 93.7% (95% 
CI [88.0-96.7)]. This implies that the APTT test is capable 
of detecting 93.7% of hypercoagulable cases among 
T2DM patients and only 6.3% will be missed as these will 
be reported as negative. Therefore APTT tests have higher 
probability of detecting hypercoagulable states in T2DM 
than PT test. 
Both APTT and PT tests had acceptable specificity. 
However APTT had a higher specificity 95.4% (95% CI 
[88.8-98.2]) than PT test 90.8% (95% CI [82.9-94.3]). 
This implies that the probability of T2DM patients who 
were not truly hypercoagulable and gives normal APTT 
and PT results was 95.4% and 90.8% respectively. Which 
means only 4(4.6%) and 8(9.2%) tests gave false positive 
test results for PT and APTT respectively. 
APTT test had a higher PPV 96.7% (95% CI [91.9-98.7)] 
than PT test 89.7% (95% CI 81.0-94.7]). This can be 
interpreted to mean that 118(96.7%) and 70(89.7%) 
positive APTT and PT test results respectively were truly 
hypercoagulable cases.
PT test results had a very low NPV of 58.8% as compared 
to APTT tests which had 91.2%. This means 79(58.8%) of 
negative PT test results were true negatives (not 
hypercoagulable) while 56(41.1%) were False Negatives 
(Hypercoagulable). From the literature searched so far, no 
diagnostic study has been done to specifically evaluate 
suitability of PT and APTT in detection of 
hypercoagulable states among T2DM patients. Loog T.W 
(2003) reported that the acceptable sensitivity, PPV and 
NPV should be above 90% (26). From the results obtained 
in this study APTT was found to be a suitable screening 
test for hypercoagulability in T2DM patients because all 
the parameters were above 90%. Though PT had 
acceptable specificity, the test is not suitable for use as a 
screening test for hypercoagulability in T2DM patients 
because it had very low sensitivity and negative predictive 
values. This entails that APTT is a better predictor of 
hypercoagulable state than PT in T2DM patients. 
Furthermore, APTT is a better discriminator for non-
hypercoagulable states in T2DM patients. 
Positive and negative predictive values vary according to 
the prevalence of the condition under study (26). 
Therefore it would be wrong for predictive values 
determined for one population to be applied to another 
population with a different prevalence. In this case APTT 
tests could only be used among T2DM patients and not the 
general population because hypercoagulability may be 
very low in the population and hence low predictive 
values even if the test is highly sensitive and specific.
There are limitations with APTT test, for example 
possible pre-analytical errors that could occur during 
venepuncture procedure or during sample collection. 
Inappropriate blood taking procedure may lead to 
coagulation factors activation and falsely giving a 
shortened APTT results. Other problem with APTT is the 
consistency in reporting the results. The coagulation 
laboratory should practice an appropriate quality 
procedure, including accuracy and precision testing, 
participation in internal and external quality assurance 
programme, establishment of a normal reference ranges 
and other related requirements.
Validation process should be done regularly whenever 
changes occur in the reagents (including lot number), 
equipments and etc. Laboratories running APTT and other 
haemostatic tests should follow the standard guideline for 
coagulation study to avoid errors (pre-analytical, 
analytical and post analytical) by practicing a regular 
auditing, considering the use of uncertainty of 
measurement in the results reporting (or when consulted) 
and verifying the correct normal reference ranges for local 
use. By doing this, the finding of shortened APTT can be 
recognized consistently in cases with high coagulation 
factors or due to other reasons that can contribute to this 
effect. Ability to detect the evidence of hypercoagulable 
state through this test is strictly dependent on the 
laboratory performance in their practice.
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CONCLUSION
T2DM patients had shorter APTT-PT and higher 
fibrinogen and VWF than the healthy non-diabetic control 
participants contributing to increased prevalence of 
hypercoagulability in diabetic patients than control 
participants. APTT could be used as a marker of 
hypercoagulability in T2DM patients because it is 
economical, easier to perform, very sensitive, specific and 
have high Positive and Negative Predictive Values. 
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DEFINITIONS
Hypercoagulability- Abnormality of blood coagulation 
that increases the risk of thrombosis.
Sensitivity (“positivity in disease”) refers to the 
proportion of participants who have the target condition 
(reference standard positive) and give positive test results. 
Specificity (“negativity in health”) is the proportion of 
participants without the target condition and give negative 
test results. 
Positive predictive value is the proportion of positive 
results that are true positive (i.e. have the target condition) 
whereas negative predictive value is the proportion of 
negative results that are true negatives (i.e. do not have the 
target condition).
ABBREVIATIONS USED
APTT: Activated Partial Thromboplastin Time; CEBM: 
Center for Evidence Based Medicine; NCH: Ndola 
Central Hospital; NPV: Negative Predictive Value; 
OPD: Out Patient Department; PPV: Positive Predictive 
Value; PT: Prothrombin Time; 
ROS: Reactive Oxygen Species; T2DM: Type 2 Diabetes 
Mellitus; TF: Tissue factor; UNZA-BREC: University 
of Zambia Biomedical Research Committee;
 VWF: Vonwillebrand's factor.
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